全文获取类型
收费全文 | 731篇 |
免费 | 44篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 44篇 |
妇产科学 | 15篇 |
基础医学 | 83篇 |
口腔科学 | 3篇 |
临床医学 | 52篇 |
内科学 | 194篇 |
皮肤病学 | 47篇 |
神经病学 | 57篇 |
特种医学 | 29篇 |
外科学 | 89篇 |
综合类 | 3篇 |
一般理论 | 3篇 |
预防医学 | 32篇 |
眼科学 | 8篇 |
药学 | 51篇 |
肿瘤学 | 71篇 |
出版年
2023年 | 3篇 |
2022年 | 7篇 |
2021年 | 18篇 |
2020年 | 15篇 |
2019年 | 17篇 |
2018年 | 34篇 |
2017年 | 23篇 |
2016年 | 28篇 |
2015年 | 28篇 |
2014年 | 33篇 |
2013年 | 33篇 |
2012年 | 47篇 |
2011年 | 61篇 |
2010年 | 51篇 |
2009年 | 26篇 |
2008年 | 39篇 |
2007年 | 50篇 |
2006年 | 42篇 |
2005年 | 39篇 |
2004年 | 35篇 |
2003年 | 29篇 |
2002年 | 31篇 |
2001年 | 11篇 |
2000年 | 5篇 |
1999年 | 7篇 |
1998年 | 7篇 |
1997年 | 3篇 |
1996年 | 5篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1992年 | 5篇 |
1990年 | 1篇 |
1989年 | 6篇 |
1988年 | 7篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1967年 | 1篇 |
1964年 | 1篇 |
1960年 | 1篇 |
1949年 | 1篇 |
排序方式: 共有783条查询结果,搜索用时 15 毫秒
91.
92.
Liposomes are well-established nanocarriers for improving the therapeutic index of anticancer agents. A remarkable understanding in the pathophysiology of breast cancer progression has emerged with information on the involved specific biomolecules, which may serve as molecular targets for its therapy. Hormonal and nonhormonal receptors can both be exploited for targeting to breast cancer cells. Targeted delivery of cytotoxic drugs using liposomes is a novel approach for breast cancer therapy. In the present article, we summarize molecular targets present on the breast cancer cells. Recent developments in liposome-based delivery of bioactives for selective treatments of breast cancer are discussed. In addition, utilization of bioenvironmental conditions of tumor for liposome-based targeted delivery is also summed up. 相似文献
93.
Pooja Yadav Prasenjit Das Bijay R. Mirdha Siddhartha Datta Gupta Shinjini Bhatnagar Ravinder M. Pandey Govind K. Makharia 《Indian journal of gastroenterology》2011,30(1):22-28
Aim
Tropical sprue was considered to be the most important cause of malabsorption in adults in India. However, several reports indicate that celiac disease is now recognized more frequently. 相似文献94.
C. difficile associated diarrhea (CDAD) is now considered to be one of the commonest causes of nosocomial diarrhea. CDAD, once considered to be a "nuisance" disease, has lately become a "killer" disease with appearance of a hypervirulent strain, toxinotype III. Although the incidence and severity of CDAD have increased in the western world especially in health care settings; it still is under-recognized in India and Asia. Any episode of diarrhea with fever and leucocytosis in a patient on some antibiotics in a health care setting is strong pointer towards presence of CDAD. Clinical suspicion is usually confirmed by ELISA based C. difficile toxin assays in the stool sample. The aim of therapy is to restore normal colonic microflora, resulting in the elimination of C. difficile. Treatment of C.difficile needs to be individualized depending on the severity of the disease and patient characteristics. Majority of patients will require antibiotic therapy and, whenever possible, discontinuation of the predisposing antibiotics. Metronidazole and vancomycin are the mainstay of the treatment of CDAD, as both these agents are highly active against all strains of pathogenic C.difficile. Neither of these drugs is however effective for the carrier state of C. difficile. Approximately 15%-30% of patients experience a symptomatic recurrence after discontinuation of antibiotics. Control of health care associated CDAD involves a range of primarily preventive measures including proper hand hygiene, use of personal protective equipment, environmental decontamination, isolation or cohort nursing and adequate treatment of CDAD cases. 相似文献
95.
Deepti Upadhyay Alka Singh Prasenjit Das Jiya Mehtab Siddhartha Dattagupta Vineet Ahuja Govind K. Makharia Naranamangalam R. Jagannathan Uma Sharma 《NMR in biomedicine》2020,33(8)
Celiac disease (CeD) is an autoimmune enteropathy caused by gluten intake in genetically predisposed individuals. We investigated the metabolism of CeD by metabolic profiling of intestinal mucosa, blood plasma and urine using NMR spectroscopy and multivariate analysis. The metabolic profile of the small intestinal mucosa was compared between patients with CeD (n = 64) and disease controls (DCs, n = 30). The blood plasma and urinary metabolomes of CeD patients were compared with healthy controls (HCs, n = 39). Twelve metabolites (proline (Pro), arginine (Arg), glycine (Gly), histidine (His), glutamate (Glu), aspartate, tryptophan (Trp), fumarate, formate, succinate (Succ), glycerophosphocholine (GPC) and allantoin (Alln)) of intestinal mucosa differentiated CeD from controls. The metabolome of blood plasma with 18 metabolites (Pro, Arg, Gly, alanine, Glu, glutamine, glucose (Glc), lactate (Lac), acetate (Ace), acetoacetate (AcAc), β‐hydroxybutyrate (β‐OHB), pyruvate (Pyr), Succ, citrate (Cit), choline (Cho), creatine (Cr), phosphocreatine (PCr) and creatinine) and 9 metabolites of urine (Pro, Trp, β‐OHB, Pyr, Succ, N‐methylnicotinamide (NMN), aminohippurate (AHA), indoxyl sulfate (IS) and Alln) distinguished CeD from HCs. Our data demonstrated changes in nine metabolic pathways. The altered metabolites were associated with increased oxidative stress (Alln), impaired healing and repair mechanisms (Pro, Arg), compromised anti‐inflammatory and cytoprotective processes (Gly, His, NMN), altered energy metabolism (Glc, Lac, β‐OHB, Ace, AcAc, Pyr, Succ, Cit, Cho, Cr and PCr), impaired membrane metabolism (GPC and Cho) and intestinal dysbiosis (AHA and IS). An orthogonal partial least square discriminant analysis model provided clear differentiation between patients with CeD and controls in all three specimens. A classification model built by combining the distinguishing metabolites of blood plasma and urine samples gave an AUC of 0.99 with 97.7% sensitivity, 93.3% specificity and a predictive accuracy of 95.1%, which was higher than for the models built separately using small intestinal mucosa, blood plasma and urine. In conclusion, a panel of metabolic biomarkers in intestinal biopsies, plasma and urine samples has potential to differentiate CeD from controls and may complement traditional tests to improve the diagnosis of CeD. 相似文献
96.
Debu Tripathy Seock-Ah Im Marco Colleoni Fabio Franke Aditya Bardia Nadia Harbeck Sara A Hurvitz Louis Chow Joohyuk Sohn Keun Seok Lee Saul Campos-Gomez Rafael Villanueva Vazquez Kyung Hae Jung K Govind Babu Paul Wheatley-Price Michelino De Laurentiis Young-Hyuck Im Sherko Kuemmel Yen-Shen Lu 《The lancet oncology》2018,19(7):904-915
97.
Sanjeev Kumar Shukla Govind Singh K. S. Shahi Bhuvan Prabhat Pant 《Journal of gastrointestinal cancer》2018,49(1):9-15
Background
Gallbladder cancer is the most common malignant cancer of the bile ducts and third most common gastrointestinal malignant in the world for public health. Its relatively low incidence and confused symptoms result in advanced disease at the time of presentation, contributing to poor prognosis and reduced survival associated with this disease. The main function of the gallbladder is to store excreted bile acids from the liver in preparation for a meal. Its main risk factor is prolonged exposure to biliary calculations, although bacterial infections and other inflammatory conditions are associated. Chronic inflammatory bowel conditions are associated with gallbladder cancer. T stage translates to identifying residual disease at reoperation for incidental gallbladder cancer and residual disease negatively affects survival.Conclusion
It is the most common cancer of gallbladder, gallbladder cancer remains a rare disease. Gallbladder cancer is a rare disease that can be accidentally diagnosed after cholecystectomy or accidentally, often with more advanced disease. The prognosis is generally extremely poor and improvements in surgical resection of this approach have to be re-evaluated, while the role of chemotherapy and radiotherapy remains controversial.98.
G.W. Fuller O. Govind R. Tucker M. Raftery 《Journal of Science and Medicine in Sport》2018,21(4):347-351
Objectives
To establish normative reference data for the SCAT3 in professional Rugby Union players.Design
A cross sectional study in professional Rugby Union players competing in national and international professional competitions between 2015 and 2016.Methods
The SCAT3 was administered pre-season or prior to tournaments. Data was collected electronically using a custom tablet application. SCAT3 subcomponents distributions were described and normative ranges determined using percentile cut-offs for average, unusually low/high, and extremely low/high scores. The association between player characteristics and performance in SCAT3 subcomponents was also investigated in exploratory analyses.Results
A total of 3611 professional Rugby Union players were included. The most common baseline symptom was fatigue (14%). The symptom score median (md) was 0 (interquartile range (IQR) = 0–1). Symptom severity md was 0 (IQR = 0–1). The md of the SAC score was 28 (IQR = 26–29). The md of the MBESS was 2 (IQR = 0–4). The Tandem gait md was 11.1 s (IQR = 10.0–12.7 s). Upper limb coordination was normal in 98.4%. Younger age and lower educational level were associated with worse performance on delayed recall and reverse month sub-components of the SCAT3 (p < 0.0001). No statistically significant differences in SCAT3 subcomponents were evident across gender.Conclusions
Representative normative reference values for the SCAT3 among professional Rugby Union players are provided. Baseline performance on concentration and delayed recall tests may be lower in younger athletes or in those with lower educational level. 相似文献99.
Udit Chander Rebecca J. Leeman-Neill Govind Bhagat 《Current hematologic malignancy reports》2018,13(4):308-317
Purpose of Review
To provide an update on the pathogenesis of enteropathy-associated T cell lymphoma (EATL) and its relationship with refractory celiac disease (RCD), in light of current knowledge of immune, genetic, and environmental factors that promote neoplastic transformation of intraepithelial lymphocytes (IELs).Recent Findings
EATL frequently evolves from RCD type II (RCD II) but can occur “de novo” in individuals with celiac disease. Recurrent activating mutations in members of the JAK/STAT pathway have been recently described in EATL and RCD II, which suggests deregulation of cytokine signaling to be an early event in lymphomagenesis. Intraepithelial T cells are presumed to be the cell of origin of EATL (and RCD II). Recent in vitro molecular and phenotypic analyses and in vivo murine studies, however, suggest an origin of RCD II from innate IELs (NK/T cell precursors), which could also be the cell of origin of RCD II-derived EATL.Summary
The immune microenvironment of the small intestinal mucosa in celiac disease fosters the development of EATL, often in a multistep pathway.100.